Skip to main content

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Recruiting · Phase 1, Phase 2 · NCT04988555

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes

At a glance

Research payments reported, 2025
$3.4M
U.S. investigators named
38
Sites paid
50
Planned or actual enrollment
606

About the trial

Sponsor
Sumitomo Pharma America, Inc.
Tested
Enzomenib (drug), azoles (drug), Venetoclax (drug), Gilteritinib (drug), Azacitidine (AZA) (drug), Intensive chemotherapy with 7 + 3 (drug)
Dates
Started 2022-02-28; completion 2027-12-31
Results posted
Not yet

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

From ClinicalTrials.gov, last updated 2026-03-24. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sumitomo Pharma America, Inc. reported $3.4M in research payments for this study in 2025 (344 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Sarah Cannon Research Institute LLC $608,642
  • University of Utah Hospital and Clinics, UT $402,546
  • University of Miami $345,868
  • Ut MD Anderson Cancer Center $312,094
  • Johns Hopkins University $269,257
  • Duke Cancer Institute $164,811
  • Dana-Farbermass General Brigham Cancer Care Inc $141,262
  • Northwestern University $138,264
  • Comprehensive Cancer Center $109,290
  • University of North Carolina at Chapel Hill $81,340
  • Wake Forest University Health Sciences $78,947
  • Rutgers the State University $72,241
  • University of Virginia Medical Center, VA $71,204
  • Hoag Memorial Hospital Presbyterian $69,141
  • Icahn School of Medicine at Mount Sinai $68,929
  • Allegheny Singer Research Institute $61,215
  • Tufts Medical Center, MA $60,500
  • Intermountain Medical Center, UT $56,204
  • The Trustees of Columbia Univ in The City of Ny $44,211
  • The Medical University of South Carolina $41,217
  • Washington University $24,280
  • Loyola University of Chicago $22,840
  • Massachusetts General Hospital $21,710
  • Ohio State University $21,599
  • VA Cancer Specialists $17,934
  • Lds Hospital, UT $15,232
  • Morristown Medical Center, NJ $11,570
  • Duke University $10,997
  • Thomas Jefferson University $7,361
  • Health Research Inc Roswell PArk Division $7,295
  • Roswell PArk Comprehensive Cancer Center $6,903
  • Medical University of South Carolina $6,566
  • Sibley Memorial Hospital $6,455
  • City View Medical Office $6,365
  • Lccc- Clinical Trials Office $6,200
  • Willamette Valley Cancer Institute $5,800
  • Scri St David's South Austin Medical Center (samc) $4,954
  • West Penn Hospital $4,647
  • Cbh Health LLC $3,869
  • Rutgers Cancer Institute of New Jersey $3,829
  • Univ of Maryland $3,682
  • Atrium Health Wake Forest Baptist $3,673
  • Tufts University $3,382
  • Stanford University $1,717
  • Columbia University $1,696
  • The Ohio State University Clinical Trials Office $972
  • University of Colorado Medicine $860
  • Duke Abmt Clinic $546
  • Robert H Lurie Comprehensive Cancer Center Northwestern University $320
  • Musc Hollings Cancer Center $165

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.